# An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Source: https://onco.cc/trials/nct05022901/  
OnCo record `nct05022901` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Melphalan in melanoma and uveal melanoma, run by Delcath Systems Inc., active and no longer recruiting.

## Summary

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma is a phase 3 interventional study registered as NCT05022901 by Delcath Systems Inc., with 30 participants planned, started 2022-06-10 and due to reach its primary completion in 2024-03-01. Interventions recorded: Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS). Conditions listed: Metastatic Ocular Melanoma, Metastatic Uveal Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05022901
- Phase: 3
- Setting: An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
- Sponsor: Delcath Systems Inc.
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT05022901: https://clinicaltrials.gov/study/NCT05022901

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- drugs: [Melphalan (including hepatic delivery system)](https://onco.cc/drugs/melphalan/)
- companies: [Delcath Systems](https://onco.cc/companies/delcath/)

---
JSON: https://onco.cc/api/v1/entities/nct05022901.json